Guidance for clinical trials with decentralized elements.: H169-14/2026E-PDF
"This guidance outlines regulatory considerations for conducting clinical trials with decentralized elements in Canada. These considerations are supported by Part C, Division 5 of the Food and Drug Regulations (FDR) and the International Council for Harmonisation’s Guideline for Good Clinical Practice (ICH E6)"--Overview, Purpose, page 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.967064&sl=0
| Department/Agency |
|
|---|---|
| Title | Guidance for clinical trials with decentralized elements. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 1 online resource (iii, 52 pages) |
| ISBN | 9781100010700 |
| Catalogue number |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: